NASDAQ:FWP - Forward Pharma A/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.81 +0.14 (+5.24 %)
(As of 06/21/2018 01:00 AM ET)
Previous Close$2.67
Today's Range$2.70 - $2.82
52-Week Range$1.63 - $30.00
Volume23,000 shs
Average Volume115,491 shs
Market Capitalization$128.34 million
P/E RatioN/A
Dividend Yield848.27%
Beta1.64
Forward Pharma A/S logoForward Pharma A/S operates as a biopharmaceutical company. The company focuses on developing FP187, a proprietary formulation of dimethyl fumarate, which has been completed Phase II clinical trials used for the treatment of various inflammatory and neurological indications, including multiple sclerosis and other immune disorders, such as psoriasis. Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark.

Receive FWP News and Ratings via Email

Sign-up to receive the latest news and ratings for FWP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FWP
CUSIPN/A
Phone45-3344-4242

Debt

Debt-to-Equity RatioN/A
Current Ratio5.22
Quick Ratio5.22

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.25 billion
Price / Sales0.11
Cash Flow$20.0714 per share
Price / Cash0.14
Book Value$1.90 per share
Price / Book1.48

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees12
Outstanding Shares47,180,000

Forward Pharma A/S (NASDAQ:FWP) Frequently Asked Questions

What is Forward Pharma A/S's stock symbol?

Forward Pharma A/S trades on the NASDAQ under the ticker symbol "FWP."

How often does Forward Pharma A/S pay dividends? What is the dividend yield for Forward Pharma A/S?

Forward Pharma A/S declared an annual dividend on Thursday, August 24th. Investors of record on Thursday, September 7th will be paid a dividend of $22.903 per share on Monday, September 11th. The ex-dividend date is Wednesday, September 6th. View Forward Pharma A/S's Dividend History.

How were Forward Pharma A/S's earnings last quarter?

Forward Pharma A/S (NASDAQ:FWP) released its quarterly earnings results on Thursday, September, 1st. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.06. View Forward Pharma A/S's Earnings History.

What price target have analysts set for FWP?

1 brokers have issued twelve-month price objectives for Forward Pharma A/S's shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Forward Pharma A/S's stock price to reach $6.00 in the next year. View Analyst Ratings for Forward Pharma A/S.

Who are some of Forward Pharma A/S's key competitors?

Who are Forward Pharma A/S's key executives?

Forward Pharma A/S's management team includes the folowing people:
  • Dr. Claus Bo Svendsen M.D., Ph.D., CEO & Principal Financial Officer (Age 41)
  • Mr. Thomas Carbone, Principal Accounting Officer, VP of Fin. and Controller (Age 61)

Has Forward Pharma A/S been receiving favorable news coverage?

News headlines about FWP stock have trended positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Forward Pharma A/S earned a daily sentiment score of 0.34 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.44 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Forward Pharma A/S's major shareholders?

Forward Pharma A/S's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (19.30%), BVF Inc. IL (10.08%) and Newtyn Management LLC (0.62%). View Institutional Ownership Trends for Forward Pharma A/S.

Which major investors are selling Forward Pharma A/S stock?

FWP stock was sold by a variety of institutional investors in the last quarter, including Newtyn Management LLC. View Insider Buying and Selling for Forward Pharma A/S.

Which major investors are buying Forward Pharma A/S stock?

FWP stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL. View Insider Buying and Selling for Forward Pharma A/S.

How do I buy shares of Forward Pharma A/S?

Shares of FWP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Forward Pharma A/S's stock price today?

One share of FWP stock can currently be purchased for approximately $2.81.

How big of a company is Forward Pharma A/S?

Forward Pharma A/S has a market capitalization of $128.34 million and generates $1.25 billion in revenue each year. Forward Pharma A/S employs 12 workers across the globe.

How can I contact Forward Pharma A/S?

Forward Pharma A/S's mailing address is Ostergade 24A 1, COPENHAGEN G7, 1100. The biotechnology company can be reached via phone at 45-3344-4242 or via email at [email protected]


MarketBeat Community Rating for Forward Pharma A/S (FWP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about Forward Pharma A/S and other stocks. Vote "Outperform" if you believe FWP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FWP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.